Tıp Fakültesi / Faculty of Medicine
Permanent URI for this collectionhttps://hdl.handle.net/11727/1403
Browse
6 results
Search Results
Item The Protective Effect of Metformin Against the Noise-Induced Hearing Loss(2018) Kesici, Gulin Gokcen; Ocal, Fatma Ceyda Akin; Gurgen, Seren Gulsen; Erdem, Saban Remzi; Ogus, Ersin; Erbek, Hatice Seyra; Ozluoglu, Levent Naci; 0000-0003-0409-6225; 0000-0002-7537-2170; 0000-0002-9877-421X; 0000-0002-2150-0237; 30306316; AAT-2326-2021; AAJ-2370-2021; AAJ-1058-2021; AAI-8020-2021ObjectiveTo test the protective effect of metformin against noise-induced hearing loss.Methods24 rats were included in the study. The first group was exposed to noise only, the second group took metformin, the third group was exposed to noise and took metformin, and the fourth group was neither exposed to noise nor took metformin as control group. After measurement of baseline DPOAE and ABR of rats, the metformin group and the metformin+noise group received 300mg/kg/day metformin via gavage for 10days. On the 11th day, group 1 and group 3 were exposured to white noise at 105dB SPL for 15h. After noise exposure, DPOAE and ABR measurements of all rats were repeated on days 1st, 7th, and 21st. At the end of the study, all animals were sacrificed and cochlear tissues were separated for immunohistochemical assessments.ResultsABR threshold values and DPAOE measurements of groups 1 and 3 were deteriorated on the 1st day after noise, while deterioration in group 1 continued on 7th and 21st days, but normalized on 7th day in group 3. After immune staining, a significant immunoreaction was observed in the noise group, while the reaction in the noise+metformin group was close to the control group.ConclusionMetformin has a protective effect on noise-induced hearing loss in rats. As a conclusion, it is determined that metformin protects from permanent threshold shift in rats. It can be considered a good alternative for protecting noise-induced hearing loss.Item Evaluation of Electrodermal Activity and Anxiety Behaviors in Diabetic Rats Given Vildagliptin and Metformin(2022) Shawesh, Muftah; Alshareef, Mohammed; Boyuk, Gulbahar; Yigit, Ayse Arzu; Dolu, NazanItem Prognostic Factors in Squamous Cell Carcinoma of the Vulva: a Retrospective Multicenter Study(2020) Kuru, Oguzhan; Akgor, Utku; Cakir, Ilker; Tosun, Ozgur; Yuksel, Ilkbal Temel; Ulker, Volkan; Meydanli, Mutlu; Sanci, Muzaffer; Gokcu, Mehmet; Topuz, Samet; Yildiz, Ferah; Sakinci, Mehmet; Salman, Mehmet Coskun; Ozgul, Nejat; Yuce, Kunter; Ayhan, Ali; AAJ-5802-2021The study aim to determine the clinicopathological factors for disease-free survival (DFS) and overall survival (OS) in women with vulvar cancer and to analyze the the possible effect of metformin on survival of the patients. From 2011 to 2017, medical records of 142 patients who underwent primary radical surgery for VC at 6 referral centers in Turkey were collected, retrospectively. The median age of the cohort was 67.0 years. 124 patients underwent radical surgery and inguinofemoral lymphadenectomy. The overall recurrence rate was 33.8% within a median follow-up time of 22 months. Five-year DFS and OS rates were 55.8% and 62.6%, respectively. Multivariate analysis showed surgical margin (HR:6.4, p= 0.017 for DFS; HR: 13.6, p=0.009 for OS) and lymph node metastasis (HR: 4.1, p= 0.014 for DFS; HR: 6.3, p= 0.020 for OS) were the independent prognostic factors. There was no statistically difference in DFS and OS for patients who had used metformin.Item Metformin Decreases Thyroid Volume and Nodule Size in Subjects with Insulin Resistance: A Preliminary Study(2016) Anil, Cuneyd; Kut, Altug; Atesagaoglu, Berna; Nar, Asli; Tutuncu, Neslihan Bascil; Gursoy, Alptekin; 26618447Objective: The aim of this study was to investigate the effects of metformin on thyroid volume and nodule size. Subjects and Methods: Prospective data were gathered on 100 newly diagnosed subjects with insulin resistance (68 female, 32 male) between August 2008 and May 2010. Each subject followed a standard diet and exercise program, and received 1,700 mg/day of metformin therapy for 6 months. The height, weight, waist circumference (WC) and thyroid hormone levels of each subject were measured. Additionally, the dimensions of the thyroid lobes and maximum diameter of each thyroid nodule were determined by ultrasonography. BMI and thyroid volumes were also calculated. Insulin resistance was estimated by homeostasis model assessment. All these parameters were measured at the beginning and at the end of the treatment period. Results: BMI and WC decreased significantly after metformin therapy (34.5 +/- 5.1 vs. 32.7 +/- 4.8, p < 0.0001, and 106.3 +/- 11.8 vs. 101.8 +/- 19.0 cm, p = 0.008, respectively). Insulin resistance also decreased after metformin therapy (4.5 +/- 1.9 vs. 2.9 +/- 1.7, p < 0.0001). The mean thyroid volume (22.5 +/- 11.2 vs. 20.3 +/- 10.4 ml, p < 0.0001) and mean thyroid nodule size (12.9 +/- 7.6 vs. 11.7 +/- 7.2 mm, p < 0.0001) also decreased after treatment. Conclusion: In subjects with insulin resistance, metformin therapy significantly decreased thyroid volume and nodule size. (C) 2015 S. Karger AG, BaselItem Metformin: Hype or Hope for Cancer(2017) Nar, Asli; 0000-0003-0998-8388; AAA-2743-2021Current studies show that especially pancreatic, liver, endometrial, colorectal, bladder and breast cancer incidences are increased by the presence of type 2 diabetes mellitus (T2DM). Possible links between T2DM and cancer include hyperinsulinemia, dysregulation of adipocytokines and hyperglycemia as well as shared confounding risk factors. There is evidence emerging from experimental and clinical studies that metformin can play a crucial anti-cancereous role. Since 2005, multiple studies showed the association between metformin and the reduction of risk in cancers of pancreas, colorectal, stomach, liver, breast and esophagus in diabetes cases. It was also claimed to improve survival in some cancers. Metformin is an insulin sensitizer and mainly acts through inhibiting hepatic gluconeogenesis by activating LKB1/AMP-activated protein kinase (AMPK). Metformin was found to have anti-cancerous and anti-metastatic effects mainly through activating AMPK dependent and independent signaling; inhibiting mTOR, MAPK, HER2, NF-kappa B, IGF signaling pathways and with its possible immuno-modulatory effects. Further studies are needed to evaluate the potential of metformin as adjuvant therapy for cancer especially in non-diabetic patients.Item Metformin kullanımının tiroid volüm ve fonksiyonlarına etkisi(Başkent Üniversitesi Tıp Fakültesi, 2011) Ateşağaoğlu, Berna; Nar, Aslıİnsülin direnci ve ilişkili metabolik bozuklukların tiroid bezinde ortaya çıkardığı fonksiyonel ve morfolojik değişiklikler son dönemin sıcak gündemini oluşturmaktadır. Önceki çalışmalarda insülin direnci (ID) olan hastalarda tiroid hacmi ve nodül prevelansının artmış olduğu gösterilmiştir. Bu çalışmada metforminin tiroid hacmi ve nodül boyutu üzerine etkilerini araştırdık. ID olan yeni tanı almış obez hastalar (n: 100; 68 kadın, 32 erkek) Ağustos 2008 ile Mayıs 2010 arasında prospektif olarak takip edildi. Tüm katılımcılara metformin tedavisinden önce ve 6 ay sonra serum TSH, serbest T3, serbest T4 ve tiroid ultrasonografisi yapıldı. Metformin tedavisinden sonra ortalama vücut kitle indeksi (VKİ) ve bel çevresi (BÇ) anlamlı ölçüde azalmıştır (34.5 ± 5.1 kg/m2 iken 32.7 ± 4.8 kg/m2 ve 106.3 ± 11.8 cm iken 101.8 ± 19.0 cm, sırası ile) (BMI için P < 0.0001 ve BÇ için P = 0.008). Hemostaz model değerlendirmesi ile bulunan ID de metformin tedavisi ile azalmıştır (4.5 ± 1.9 iken 2.9 ± 1.7, P < 0.0001). Tedavi sonrası ortalama TSH düzeyi azalmış (1.8 ± 1.0 mIU/L iken 1.5 ± 0.8 mIU/L, P < 0.0001), ortalama serbest T3 yükselmiş (2.7 ± 0.7 pg/mL iken 3.0 ± 0.8 pg/mL, P = 0.03), ve ortalama serbest T4 benzer bulunmuştur (1.4 ± 0.6 ng/dL iken 1.5 ± 1.3 ng/dL, P > 0.5). Ortalama tiroid hacmi (22.5 ± 11.2 mL iken 20.3 ± 10.4 mL, P < 0.0001) ve ortalama tiroid nodül boyutu (12.9 ± 7.6 mm iken 11.7 ± 7.2 mm, P < 0.0001) da tedavi sonrası azalmıştır. Cinsiyetin klinik göstergelerdeki değişim üzerinde istatistiksel olarak anlamlı etkisi yoktu (p>0,05) . Yaşın ise sadece volüm değişimi üzerinde anlamlı etkisi olup 50 yaş üstü grubunda volüm daha fazla azalmıştı (22,4 ±11,1 mL iken 20,2±10,4 mL, p=0,006). Sonuçlar, ID olan hastalarda metformin tedavisinin tiroid hacmini ve nodül boyutunu anlamlı olarak azalttığını göstermektedir.